Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedFeb 14, 2026
DataAggregated Company Financials
Companies5
  • 7D-2.4%
  • 3M-5.8%
  • 1Y0.7%
  • YTD-6.2%

Over the last 7 days, the Biotech industry has dropped 3.6%, driven by a pullback from Genmab of 2.7%. Over the last year, the industry has been flat overall. Looking forward, earnings are forecast to decline by 6.6% per year.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 14 Feb 2026DKK 160.9bDKK 40.3bDKK 18.9b6.1x8.5x4x
Mon, 12 Jan 2026DKK 180.1bDKK 40.8bDKK 19.1b6.4x9.4x4.4x
Wed, 10 Dec 2025DKK 174.7bDKK 40.8bDKK 19.1b6.1x9.2x4.3x
Fri, 07 Nov 2025DKK 160.0bDKK 39.2bDKK 16.9b10.3x9.5x4.1x
Sun, 05 Oct 2025DKK 184.1bDKK 38.8bDKK 16.7b12.7x11x4.7x
Tue, 02 Sep 2025DKK 151.6bDKK 38.8bDKK 16.8b11.6x9x3.9x
Thu, 31 Jul 2025DKK 133.3bDKK 27.4bDKK 7.5b13x17.8x4.9x
Sat, 28 Jun 2025DKK 120.1bDKK 26.9bDKK 7.3b10.5x16.4x4.5x
Mon, 26 May 2025DKK 126.6bDKK 28.0bDKK 7.9b10.3x16x4.5x
Wed, 23 Apr 2025DKK 121.2bDKK 27.3bDKK 7.7b10.9x15.8x4.4x
Fri, 21 Mar 2025DKK 140.6bDKK 27.3bDKK 7.7b12.1x18.3x5.1x
Sun, 16 Feb 2025DKK 162.8bDKK 27.7bDKK 7.8b12x20.8x5.9x
Tue, 14 Jan 2025DKK 164.7bDKK 26.0bDKK 4.7b17.4x35.1x6.3x
Thu, 12 Dec 2024DKK 172.2bDKK 26.0bDKK 4.7b17.8x36.7x6.6x
Sat, 09 Nov 2024DKK 178.0bDKK 26.0bDKK 4.3b22.2x41.4x6.8x
Mon, 07 Oct 2024DKK 173.9bDKK 25.5bDKK 5.5b21.6x31.8x6.8x
Wed, 04 Sep 2024DKK 202.3bDKK 25.5bDKK 5.5b25x37x7.9x
Fri, 02 Aug 2024DKK 205.1bDKK 24.8bDKK 5.6b18.8x36.4x8.3x
Sun, 30 Jun 2024DKK 188.2bDKK 24.8bDKK 5.6b17x33.4x7.6x
Tue, 28 May 2024DKK 179.3bDKK 24.8bDKK 5.6b18.6x31.8x7.2x
Thu, 25 Apr 2024DKK 179.0bDKK 23.9bDKK 5.0b18.6x35.5x7.5x
Sat, 23 Mar 2024DKK 193.4bDKK 23.9bDKK 5.0b19.8x38.5x8.1x
Mon, 19 Feb 2024DKK 173.5bDKK 22.8bDKK 4.2b23.6x41.1x7.6x
Wed, 17 Jan 2024DKK 173.9bDKK 23.3bDKK 4.2b24.3x41.8x7.5x
Fri, 15 Dec 2023DKK 176.4bDKK 23.3bDKK 4.2b25.9x42.4x7.6x
Sun, 12 Nov 2023DKK 168.3bDKK 22.7bDKK 4.3b21.3x39.2x7.4x
Tue, 10 Oct 2023DKK 188.7bDKK 22.0bDKK 4.7b22x39.8x8.6x
Thu, 07 Sep 2023DKK 197.4bDKK 22.0bDKK 4.7b23.1x41.8x9x
Sat, 05 Aug 2023DKK 190.1bDKK 20.6bDKK 3.9b36.7x49.1x9.2x
Mon, 03 Jul 2023DKK 198.3bDKK 19.5bDKK 4.4b41x45x10.1x
Wed, 31 May 2023DKK 209.5bDKK 19.5bDKK 4.4b41.2x47.6x10.7x
Fri, 28 Apr 2023DKK 207.8bDKK 17.9bDKK 4.1b32.5x50.7x11.6x
Sun, 26 Mar 2023DKK 194.8bDKK 17.9bDKK 3.5b30.5x55x10.9x
Tue, 21 Feb 2023DKK 210.1bDKK 14.7bDKK 3.3b32x64.2x14.3x
Price to Earnings Ratio

64.2x


Total Market Cap: DKK 210.1bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 31.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 8.5x which is lower than its 3-year average PE of 31.6x.
  • The 3-year average PS ratio of 7.1x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 79% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-0.18%
Healthcare3.28%
Biotech-2.38%
Biotech-2.38%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOPOR BioPortoDKK 0.972.3%
+DKK 10.9m		-35.5%PS13.2x

Latest News

BAVA
DKK 192.00
Bavarian Nordic
7D
-0.7%
1Y
12.2%
BIOPOR
DKK 0.97
BioPorto
7D
2.3%
1Y
-35.5%
ZEAL
DKK 399.70
Zealand Pharma
7D
-1.9%
1Y
-46.9%

ZEAL: Metabolic Collaboration Will Drive Future Upside As Profitability Assumptions Improve

Analysts have trimmed their price target for Zealand Pharma from €745.93 to €735.27, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that modestly adjust their overall valuation framework. What's in the News Zealand Pharma and OTR Therapeutics entered a multi program collaboration and license agreement focused on discovering and developing novel therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
GMAB
DKK 1,904.50
Genmab
7D
-2.7%
1Y
26.6%

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
STRAP
DKK 562.00
Strategic Partners
7D
-1.7%
1Y
-33.1%